Gene Zlotnikov

In rare disease, patient experience is the strategy. Long diagnostic journeys, limited HCP awareness, and deeply engaged patient communities demand trust-based, highly personalized engagement models. Leading organizations are moving beyond traditional commercialization to build connected ecosystems that shorten time to diagnosis, support lifelong care, and empower patients and caregivers as partners, balancing precision analytics with empathy, transparency, and ethical responsibility.

• Aligning medical, commercial, access, and advocacy teams around end-to-end rare disease experiences—from diagnosis through long-term support.
• Partnering with advocacy groups and caregivers to build credible, lived-experience–driven education and support.
• Applying predictive insights and next-best-action intelligence to engage small, high-impact HCP and patient populations compliantly.
• Focusing KPIs on time to diagnosis, initiation, persistence, satisfaction, and advocacy—where quality outweighs volume.